TGBA01AD

TGBA01AD
Clinical data
Other namesFKB01MD
Routes of
administration		By mouth
Pharmacokinetic data
Bioavailability17%
Elimination half-life4 hours

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.

See also

References

  1. 1 2 3 "FKB01MD". Fabre-Kramer. Archived from the original on 2016-03-04. Retrieved 2015-05-15.
  2. ↑ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
  3. ↑ Żmudzka E, Sałaciak K, Sapa J, Pytka K (October 2018). "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences. 210: 106–124. doi:10.1016/j.lfs.2018.08.050. PMID 30144453. S2CID 52090587.
  4. ↑ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.